Home > Press > Orphan in need of adoption
Nano therapy for ovarian cancer will enable superior tumor accumulation and retention of radioactivity, resulting in better therapuetic efficacy than existing standards of care.
Orphan in need of adoption
Philadelphia, PA | Posted on December 8th, 2006
Twenty thousand new cases of ovarian cancer are diagnosed in the United States each year. More than 75% of these patients are women with late stage ovarian cancer. The prognosis for this group is very poor: only 30% will survive five years or longer.
Even treatment for ovarian cancer can be devastating to a patient's quality of life. Treatment commonly involves invasive surgery followed by extensive chemotherapy, both of which can be physically and emotionally traumatic.
Under funding received from The Nanotechnology Institute and the National Cancer Institute, University of Pennsylvania Scientists have created a nanotechnology-based radiopharmaceutical that could potentially improve the treatment of ovarian cancer.
The proprietary platform technology specifically targets cancer cells via the folate receptor pathway, minimizing damage to surrounding non-cancerous cells. In principle, the drug will enable a higher tumor radiation dose than is possible with other radiotherapeutics, which do not deliver enough radiation to be useful for treatment.
Unfortunately, despite tremendous laboratory progress, this technology may never reach the patients who need it most. The reason is that the market opportunity for ovarian cancer is small (~$75M/year) - too small to justify development by a large multinational corporation.
"This is a platform technology with enormous potential, but its early stage means there is also enormous clinical risk," says Dr. Brian Smith, a co-inventor of the technology. "Our work with Greg Adams at the Fox Chase Cancer Center is promising, but it suggests the need for additional experiments."
Usually at this stage of development, a sponsoring company would invest and work with the scientist to further the research. However, the small market size is a significant barrier to attracting would-be investors. Dr. Smith also hopes to keep the drug affordable, launching at a price of around $5,000 instead of the $50,000 that could be charged for this type of therapy.
"What we need is an angel with personal interest," says Hugo Fitzgerald, Manager of Nanotechnology and Licensing at the University of Pennsylvania. "We have an adequate IP portfolio to justify the creation of a small start up, what we lack is the outside management to champion it and push it out of the laboratory and into the FDA approval process."
The therapeutic would likely qualify for tax credits and marketing exclusivity under the Orphan Drug Act, priority FDA review, and accelerated FDA approval. Follow on applications could include treatments for various other cancers as well as a related radiopharmaceutical for diagnostic imaging.
If interested in working with or supporting the research, please contact:
Manager Nanotechnology and Licensing
Center for Technology Transfer
University of Pennsylvania
For more information, please click here
Contact: Hugo FitzGerald
Phone: 215 573 4307
Copyright © University of Pennsylvania
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference February 17th, 2015
Iran 1st among Islamic Nations in Scientific Production, Nanotechnology February 16th, 2015
Harris & Harris Group Portfolio Company D-Wave Systems Raises an Additional $29 Million (CAD), Closing 2014 Financing at $62 Million (CAD) February 2nd, 2015
Malaysian Nanotechnology Company Nanopac Innovation Ltd. lists on the NSX January 19th, 2015
Untangling DNA with a droplet of water, a pipet and a polymer: With the 'rolling droplet technique,' a DNA-injected water droplet rolls like a ball over a platelet, sticking the DNA to the plate surface February 27th, 2015
Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015
Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations: UCLA bioengineers develop platform that offers personalized approach to treatment February 24th, 2015
Optical nanoantennas set the stage for a NEMS lab-on-a-chip revolution February 24th, 2015
Scientific breakthrough in rechargeable batteries: Researchers from Singapore and Québec Team Up to Develop Next-Generation Materials to Power Electronic Devices and Electric Vehicles February 28th, 2015
First detailed microscopy evidence of bacteria at the lower size limit of life: Berkeley Lab research provides comprehensive description of ultra-small bacteria February 28th, 2015
Leti to Offer Updates on Silicon Photonics Successes at OFC in LA February 27th, 2015
Moving molecule writes letters: Caging of molecules allows investigation of equilibrium thermodynamics February 27th, 2015
2015 Nanonics Image Contest January 29th, 2015
OCSiAl supports NanoART Imagery Contest January 23rd, 2015
EnvisioNano: An image contest hosted by the National Nanotechnology Initiative (NNI) January 22nd, 2015
Oxford Instruments Asylum Research Announces AFM Image Contest Winners January 11th, 2015